We are live on ! Find out more
CLVS

Clovis Oncology, Inc.
CLVS

Delisted

CLVS was delisted on the 20th of December, 2022.

Back to rankings

186 hedge funds and large institutions have $1.24B invested in Clovis Oncology, Inc. in 2019 Q1 according to their latest regulatory filings, with 40 funds opening new positions, 62 increasing their positions, 49 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

122% more first-time investments, than exits

New positions opened: 40 | Existing positions closed: 18

30% more capital invested

Capital invested by funds: $953M → $1.24B (+$285M)

27% more repeat investments, than reductions

Existing positions increased: 62 | Existing positions reduced: 49

25% more funds holding in top 10

Funds holding in top 10: 4 → 5 (+1)

21% more call options, than puts

Call options by funds: $50.7M | Put options by funds: $41.8M

13% more funds holding

Funds holding: 165 → 186 (+21)

Holders
186
Holders Change
+21
Holders Change %
+12.73%
% of All Funds
4.03%
Holding in Top 10
5
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+25%
% of All Funds
0.11%
New
40
Increased
62
Reduced
49
Closed
18
Calls
$50.7M
Puts
$41.8M
Net Calls
+$8.91M
Net Calls Change
-$15.7M

Top Buyers

1
HM
HealthCor Management
New York
+$35.1M
2
Westfield Capital Management
Westfield Capital Management
Massachusetts
+$20.2M
3
RG
Redmile Group
California
+$12.6M
4
CS
Candriam SCA
Luxembourg
+$12.2M
5
Point72 Asset Management
Point72 Asset Management
Connecticut
+$11.5M

Top Sellers

1
AC
Armistice Capital
New York
-$73.6M
2
CCM
Camber Capital Management
Massachusetts
-$32.6M
3
PC
PointState Capital
New York
-$18.7M
4
SC
Samlyn Capital
New York
-$15.9M
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$15.1M
Name Holding Trade Value Shares
Change 		Change in
Stake
PAI
1
Palo Alto Investors
California
$130M – – –
Vanguard Group
2
Vanguard Group
Pennsylvania
$115M +$1.73M +68,832 +2%
RG
3
Redmile Group
California
$113M +$12.6M +503,400 +12%
BlackRock
4
BlackRock
New York
$106M -$1.86M -74,312 -2%
State Street
5
State Street
Massachusetts
$84.4M +$172K +6,854 +0.2%
O
6
OrbiMed
New York
$70.3M +$2.01M +80,100 +3%
AC
7
Armistice Capital
New York
$52.1M -$73.6M -2,936,000 -58%
CCM
8
Camber Capital Management
Massachusetts
$37.2M -$32.6M -1,300,000 -46%
HM
9
HealthCor Management
New York
$34.7M +$35.1M +1,398,300 New
Fidelity Investments
10
Fidelity Investments
Massachusetts
$22.3M -$3.59M -143,152 -14%
Westfield Capital Management
11
Westfield Capital Management
Massachusetts
$20M +$20.2M +806,465 New
CS
12
Candriam SCA
Luxembourg
$19.4M +$12.2M +488,523 +167%
Citadel Advisors
13
Citadel Advisors
Florida
$16.8M +$1.58M +63,138 +10%
SIM
14
Spark Investment Management
New York
$16.7M +$5.71M +227,800 +51%
Northern Trust
15
Northern Trust
Illinois
$15.6M +$89.5K +3,570 +0.6%
Geode Capital Management
16
Geode Capital Management
Massachusetts
$15.4M +$1.18M +47,007 +8%
FCM
17
Farallon Capital Management
California
$14.9M -$10M -400,000 -40%
Point72 Asset Management
18
Point72 Asset Management
Connecticut
$14.6M +$11.5M +460,518 +363%
Goldman Sachs
19
Goldman Sachs
New York
$14.1M +$7.76M +309,533 +120%
Capital World Investors
20
Capital World Investors
California
$13.2M – – –
ECP
21
Elk Creek Partners
Colorado
$12.5M +$3.05M +121,551 +32%
Norges Bank
22
Norges Bank
Norway
$11.5M – – –
D.E. Shaw & Co
23
D.E. Shaw & Co
New York
$11.3M +$11.1M +443,569 +3,922%
Balyasny Asset Management
24
Balyasny Asset Management
Illinois
$10.5M +$1.04M +41,381 +11%
Morgan Stanley
25
Morgan Stanley
New York
$10.3M -$6.61M -263,719 -39%
1
2 3 4 5

CLVS Hedge Fund Activity: Q1 2019 in Review

186 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Clovis Oncology, Inc. (CLVS) for Q1 2019, worth a combined $1.24B — up 30% from $953M a quarter earlier.

Buyers outnumbered sellers: 40 funds opened new CLVS positions and 18 closed out — a net gain of 22 holders — while 62 added to existing stakes and 49 trimmed.

The largest buyer was HealthCor Management, opening a new position worth an estimated $35.1M. The largest seller was Armistice Capital, cutting an estimated $73.6M.

  • 186 institutional investors held Clovis Oncology, Inc. (CLVS) as of Q1 2019, up from 165 in Q4 2018.
  • Funds reported $1.24B of Clovis Oncology, Inc. stock for Q1 2019, up 30% quarter-over-quarter.
  • 40 funds opened new Clovis Oncology, Inc. positions in Q1 2019 and 18 closed out, a net change of +22 holders.
  • The largest Clovis Oncology, Inc. buyer in Q1 2019 was HealthCor Management, an estimated $35.1M added.
  • The largest Clovis Oncology, Inc. seller in Q1 2019 was Armistice Capital, an estimated $73.6M sold.

Based on aggregated 13F filings for Q1 2019.